BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer’s strategy in the wake of the Covid-19 pandemic was to use the tens of billions in cash it reaped through sales of its vaccine and antiviral to make acquisitions.

If we take a look at Pfizer’s top products for 2024, we can observe that the sales from their COVID vaccine, Comirnaty, dropped more than 50% vs. 2023 due to a decrease in vaccinations globally ...

Pharmaceutical giant Pfizer recently shared its plans to revive vaccine awareness in Mexico and become a key vaccine supplier ...

Pfizer (PFE) announced it does not anticipate significant changes to U.S. vaccine policy under the incoming Trump administration, despite vaccine skeptic Robert F. Kennedy Jr.’s nomination to ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine was viable.

Pfizer Inc. (NYSE: PFE) was one of these and dropped out of the strategy before the COVID-19 vaccine. PFE is worse than out-of-favor but still pays one of the highest dividends among DOW components.

The settlements will see BioNTech pay $791.5 million to NIH and $467 million to Penn, with Pfizer (PFE), its vaccine partner, reimbursing part of these payments.

Vaccine Development Insights Scientific Foundation Moderna and Pfizer-BioNTech vaccines are revolutionary in the field of immunology, utilizing messenger RNA (mRNA) technology to instruct cells to ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

The arrival of updated Pfizer-BioNTech and Moderna vaccines for the KP.2 variant comes well into a summer wave when Americans have struggled to find an existing shot.